scholarly journals Application of organometallic chemistry in the formulation of a modern therapeutic drug by Ag nanoparticles green-mediated by Allium to treat the breast cancer

2022 ◽  
pp. 103693
Author(s):  
Jinku Zhang ◽  
Jirui Sun ◽  
Huijuan Geng ◽  
Qiushuang Ma ◽  
Chong Li
Keyword(s):  
Breast Cancer ◽  
Organometallic Chemistry ◽  
Ag Nanoparticles ◽  
Therapeutic Drug

scholarly journals Mibefradil inhibits the proliferation of triple-negative breast cancer by targeting AURKA to regulate apoptosis signal pathway

2021 ◽  
Author(s):  
Xu Han ◽  
Xiujuan Qu ◽  
Beixing Liu ◽  
Yizhe Wang ◽  
Yang Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Molecular Docking ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Drug ◽  
Specific Gene ◽  
In Vivo Models

Abstract Background: Triple negative breast cancer (TNBC) is a tumor characterized by high recurrence and mortality, but without effective targeted therapy. It is urgent to explore new treatment strategy to improve the efficacy of TNBC therapy. Methods: Transcriptomic profiling datasets of TNBC were used for screening TNBC specific gene sets. Drug prediction was performed in Connectivity map (CMap) database. Molecular docking method was used for analyzing drug targets. In vitro and in vivo models of TNBC were constructed to examine the drug efficacy. Results: We screened out Mibefradil, a T-type Ca2+ channel blocker, might be a potential therapeutic drug for TNBC by transcriptomics and bioinformatics analysis, and verified that Mibefradil could inhibit the proliferation of TNBC cells by inducing apoptosis and cell cycle arrest. Furthermore, by network pharmacology and molecular docking analysis, AURKA was predicted as the most possible drug target of Mibefradil. Finally, it was proved that Mibefradil treatment could induce apoptosis by decreasing protein expression and phosphorylation level of AURKA in vitro and in vivo. Conclusions: Mibefradil played anti-cancer role in TNBC cells by targeting to AURKA to induce cell cycle and apoptosis. Our results repurposed Mibefradil as a potential targeted drug of TNBC and provided a fundamental research for a novel strategy TNBC treatment.

scholarly journals 191P Therapeutic drug monitoring of tamoxifen to improve adjuvant treatment of hormone sensitive breast cancer: The TOTAM study

2020 ◽  
Vol 31 ◽  
pp. S319
Author(s):  
L. Braal ◽  
A. Jager ◽  
K.M. Lommen ◽  
E. Oomen-de Hoop ◽  
P. de Bruijn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Therapeutic Drug Monitoring ◽  
Adjuvant Treatment ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Hormone Sensitive

scholarly journals Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients

2021 ◽  
Vol 122 (4) ◽  
pp. 243-256
Author(s):  
Jaroslava Roušarová ◽  
Martin Šíma ◽  
Ondřej Slanař
Keyword(s):  
Breast Cancer ◽  
Protein Kinase ◽  
Therapeutic Drug Monitoring ◽  
Cancer Treatment ◽  
Drug Monitoring ◽  
Kinase Inhibitors ◽  
Breast Cancer Treatment ◽  
Protein Kinase Inhibitors ◽  
Therapeutic Drug ◽  
Exposure Response

Protein kinase inhibitors (PKIs) represent up-to-date therapeutic approach in breast cancer treatment. Although cancer is a rapidly progressive disease, many substances, including PKIs, are usually used at fixed doses without regard to each patient’s individuality. Therapeutic drug monitoring (TDM) is a tool that allows individualization of therapy based on drug plasma levels. For TDM conduct, exposure-response relationships of drug substances are required. The pharmacokinetic data and exposure-response evidence supporting the use of TDM for 6 PKIs used in breast cancer treatment, one of the most common female tumour diseases, are discussed in this review.

Abstract B42: The sigma-2 receptor as a target for therapeutic drug delivery in triple negative breast cancer

2016 ◽  
Author(s):  
Mehran Makvandi ◽  
Estifanos D. Tilahun ◽  
Brian P. Lieberman ◽  
Kuiying Xu ◽  
Chenbo Zeng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Drug

scholarly journals Eco-friendly biosynthesis, anticancer drug loading and cytotoxic effect of capped Ag-nanoparticles against breast cancer

2017 ◽  
Vol 7 (8) ◽  
pp. 793-802 ◽  
Author(s):  
M. Naz ◽  
N. Nasiri ◽  
M. Ikram ◽  
M. Nafees ◽  
M. Z. Qureshi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Anticancer Drug ◽  
Ag Nanoparticles ◽  
Cytotoxic Effect ◽  
Drug Loading

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.

1996 ◽  
Vol 14 (5) ◽  
pp. 1581-1588 ◽  
Author(s):  
M Sandström ◽  
A Freijs ◽  
R Larsson ◽  
P Nygren ◽  
M L Fjällskog ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Half Life ◽  
Systemic Exposure ◽  
Compartment Model ◽  
Pharmacokinetic Parameters ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic ◽  
Breast Cancer Patients ◽  
Nonlinear Elimination

PURPOSE The aim of this study was to investigate the covariance between the pharmacokinetics of the three components of the FEC regimen, epirubicin (EPI), fluorouracil (5-FU), and the cyclophosphamide (CP) metabolite 4-hydroxycyclophosphamide (4-OHCP), in breast cancer patients. PATIENTS AND METHODS Data from 21 women were collected over a total of 35 cycles. 5-FU (300 to 600 mg/m2) and CP (300 to 600 mg/m2) were administered as bolus injections, whereas EPI (15 to 60 mg/m2) was administered either as a bolus injection or as an infusion. The pharmacokinetics of the component drugs were monitored using a limited sampling scheme. Population pharmacokinetic models for each of the three drugs were developed using the program NONMEM. RESULTS The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively. EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h. The elimination of 4-OHCP was monoexponential, with a mean half-life of 7 hours. The interindividual coefficients of variation (CVs) in CL were 30%, 22%, and 41% for 5-FU, EPI, and 4-OHCP, respectively. The corresponding values for intrapatient course-to-course variability in CL were 11%, 8%, and 27%. No significant correlation in any of the pharmacokinetic parameters between the drugs was found. CONCLUSION Individualization of dosing of the FEC regimen using therapeutic drug monitoring and attempts to find concentration-response relationships may be successful, but requires that the exposure of all three drugs is considered simultaneously.

scholarly journals Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

2015 ◽  
Vol 9s2 ◽  
pp. BCBCR.S29420 ◽  
Author(s):  
Mohamed I. Nounou ◽  
Fatema ElAmrawy ◽  
Nada Ahmed ◽  
Kamilia Abdelraouf ◽  
Satyanarayana Goda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Diagnosis And Treatment ◽  
Treatment Modalities ◽  
Therapeutic Drug ◽  
Screening Methods ◽  
Positive Trend ◽  
Research Papers ◽  
Novel Technologies ◽  
Cancer Management

Breast cancer is the most prevalent cancer among women worldwide. However, increased survival is due to the dramatic advances in the screening methods, early diagnosis, and breakthroughs in treatments. Over the course of the last decade, many acquisitions have taken place in this critical field of research in the pharmaceutical industry. Advances in molecular biology and pharmacology aided in better understanding of breast cancer, enabling the design of smarter therapeutics able to target cancer and respond to its microenvironment efficiently. Patents and research papers investigating diagnosis and treatment strategies for breast cancer using novel technologies have been surveyed for the past 15 years. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. This review provides an overview of breast cancer, conventional therapy, novel technologies in the management of breast cancer, and rational approaches for targeting breast cancer. Highlights Breast cancer is the most common cancer in women worldwide. However, survival rates vary widely, optimistically heading toward a positive trend. Increased survival is due to the drastic shift in the screening methods, early diagnosis, and breakthroughs in treatments. Different strategies of breast cancer classification and staging have evolved over the years. Intrinsic (molecular) subtyping is essential in clinical trials and well understanding of the disease. Many novel technologies are being developed to detect distant metastases and recurrent disease as well as to assess response to breast cancer management. Intensive research efforts are actively ongoing to take novel breast cancer therapeutics to potential clinical application. Most of the recent research papers and patents discuss one of the following strategies: the development of new drug entities that specifically target the breast tumor cells; tailor designing a novel carrier system that can multitask and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a therapeutic drug moiety with a targeting moiety, diagnostic moiety or pharmacokinetics altering moiety; or the use of innovative nontraditional approaches such as genetic engineering, stem cells, or vaccinations.

Sign in / Sign up

Export Citation Format

Share Document